Sep 18, 2018 7:05am EDT IMV Inc. Announces Early Positive Results from Phase 2 Clinical Trial of Lead Candidate DPX-Survivac in Combination with Merck’s Keytruda® in Patients with DLBCL
Sep 11, 2018 7:05am EDT IMV Inc. Announces Phase 2 Basket Trial in Collaboration with Merck to Evaluate DPX-Survivac in Combination with KEYTRUDA® Across Five Solid Tumor Indications
Aug 23, 2018 7:05am EDT IMV Inc. to Present at the H.C. Wainwright 20th Annual Global Investment Conference
Aug 09, 2018 7:05am EDT IMV Inc. Reaches Multiple Milestones in Advanced Ovarian Cancer Clinical Trial
Jul 31, 2018 7:05am EDT IMV Inc. to Announce Second Quarter 2018 Financial Results and Host Earnings Call on August 8, 2018
Jun 03, 2018 10:57am EDT IMV Inc. (Formerly Immunovaccine Inc.) Presents New Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ASCO Meeting
